Aim: To determine the impact of stages of renal dysfunction on mortality after percutaneous coronary intervention (PCI) in patients with acute coronary syndrome (ACS). Patients and Methods: A total of 449 patients (mean age 63 ± 11.9 years) with ACS after PCI were included. Serum creatinine was determined and creatinine clearance was calculated using the Modification of Diet in Renal Disease (MDRD) formula. Results: The prevalence of chronic kidney disease (CKD) defined as glomerular filtration rate (GFR) <60 mL/min per 1.73 m2 was 26.3%. After up to 787 days of follow-up, 40 patients had died. Kaplan-Meier survival analysis showed progressively higher risk for cardiovascular death from stage 1 to stage 4 of renal dysfunction. In an adjusted Cox model, gender (P < .009), age (P < .0001), total cholesterol level (P < .01), and stage of renal dysfunction (P < .04) were predictors of mortality. Conclusions: In patients with ACS after PCI, a higher stage of renal dysfunction was directly associated with higher mortality of these patients.
National Kidney Foundation.K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 suppl 1):S1-S266.
2.
Sarnak MJ, Levey AS, Schoolwerth AC, et al, and American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention.Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension. 2003;42(5):1050-1065.
Foley RN, Parfrey PS, Sarnak MJEpidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol.1998;9(12 suppl):S16-S23.
5.
Go AS, Chertow GM, Fan D., Mc Culloch CE, Hsu CYChronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004; 351(13):1296-1305.
6.
Anavekar NS, McMurray JJ, Velazquez EJ, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med. 2004;351(13): 1285-1295.
7.
Fried LP, Kronmal RA, Newman AB, et al. Risk factors for 5-year mortality in older adults: the Cardiovascular Health Study. JAMA. 1998;279(8):585-592.
8.
Manjunath G., Tighiouart H., Coresh J., et al. Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. Kidney Int. 2003;63(3):1121-1129.
9.
Garg AX, Clark WF, Haynes RB, House AAModerate renal insufficiency and the risk of cardiovascular mortality: results from the NHANESI. Kidney Int. 2002;61(4): 1486-1494.
10.
Santopinto JJ, Fox KA, Goldberg RJ, et al. Creatinine clearance and adverse hospital outcomes in patients with acute coronary syndromes: findings from the global registry of acute coronary events (GRACE). Heart. 2003; 89(9):1003-1008.
11.
Walsh CR, O’Donnell CJ, Camargo CA Jr, Giugliano RP, Lloyd-Jones DMElevated serum creatinine is associated with 1-year mortality after acute myocardial infarction. Am Heart J. 2002;144(6):1003-1011.
12.
Sadeghi HM, Stone GW, Grines CL, et al. Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction. Circulation. 2003;108(22):2769-2775.
13.
Levey AS, Bosch JP, Lewis JB, Greene T., Rogers N., Roth D.A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130(6):461-470.
14.
Levey AS, Coresh J., Balk E., et al, and the National Kidney Foundation.National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med.2003;139(2):137-147.
15.
Chadban SJ, Briganti EM, Kerr PG, et al. Prevalence of kidney damage in Australian adults: the AusDiab kidney study. J Am Soc Nephrol.2003;14(7 suppl 2): S131-S138.
16.
Viktorsdottir O., Palsson R., Andresdottir MB, Aspelund T., Gudnason V., Indridason OSPrevalence of chronic kidney disease based on estimated glomerular filtration rate and proteinuria in Icelandic adults . Nephrol Dial Transplant. 2005;20(9):1799-1807.
17.
Muntner P., Hamm LL, Kusek JW, Whelton PK, He J.The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease. Ann Intern Med. 2004;140(1):9-17.
18.
Mann JF, Gerstein HC, Pogue J., Bosch J., Yusuf S.Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med. 2001;134(8):629-636.
19.
Reis SE, Olson MB, Fried L., et al. Mild renal insufficiency is associated with angiographic coronary artery disease in women. Circulation. 2002 ;105(24):2826-2829.
20.
Manjunath G. , Tighiouart H., Ibrahim H., et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol. 2003;41(1):47-55.
21.
Henry RM, Kostense PJ, Bos G., et al. Mild renal insufficiency is associated with increased cardiovascular mortality: The Hoorn Study. Kidney Int. 2002 ;62(4): 1402-1407.
22.
Weiner DE, Tighiouart H., Stark PC, et al. Kidney disease as a risk factor for recurrent cardiovascular disease and mortality. Am J Kidney Dis. 2004 ;44(2):198-206.
23.
Muntner P., He J., Hamm L., Loria C., Whelton PKRenal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol. 2002 ;13(3):745-753.
24.
Ninomiya T. , Kiyohara Y., Kubo M., et al. Chronic kidney disease and cardiovascular disease in a general Japanese population: the Hisayama Study. Kidney Int. 2005;68(1): 228-236.
25.
Astor BC, Coresh J., Heiss G., Pettitt D., Sarnak MJKidney function and anemia as risk factors for coronary heart disease and mortality: the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J. 2006;151(2): 492-500.
26.
Nikolsky E. , Mehran R., Turcot D., et al. Impact of chronic kidney disease on prognosis of patients with diabetes mellitus treated with percutaneous coronary intervention. Am J Cardiol. 2004;94(3):300-305.
27.
Culleton BF , Larson MG, Evans JC, et al. Prevalence and correlates of elevated serum creatinine levels: the Framingham Heart Study. Arch Intern Med. 1999;159(15):1785-1790.
28.
Edwards MS, Craven TE, Burke GL, Dean RH, Hansen KJRenovascular disease and the risk of adverse coronary events in the elderly: a prospective, population-based study. Arch Intern Med. 2005;165(2):207-213.
29.
Han JH, Chandra A., Mulgund J., et al. Chronic kidney disease in patients with non-ST-segment elevation acute coronary syndromes. Am J Med. 2006;119(3):248-254.
30.
Wright RS, Reeder GS, Herzog CA, et al. Acute myocardial infarction and renal dysfunction: a high-risk combination. Ann Intern Med. 2002;137(7):563-570.
31.
Muntner P., He J., Astor BC, Folsom AR, Coresh J.Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study. J Am Soc Nephrol. 2005;16(2):529-538.
32.
Foley RN, Wang C., Collins AJ. Cardiovascular risk factor profiles and kidney function stage in the US general population: the NHANES III study. Mayo Clin Proc. 2005;80(10):1270-1277.
33.
Weiner DE, Tighiouart H., Amin MG, et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol. 2004;15(5):1307-1315.
34.
Tonelli M., Bohm C., Pandeya S., Gill J., Levin A., Kiberd BACardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency. Am J Kidney Dis. 2001;37(3):484-489.
35.
Shepherd J., Kastelein JJ, Bittner V., et al, and Treating to New Targets Investigators. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clin J Am Soc Nephrol. 2007;2(6): 1131-1139.
36.
Athyros VG, Mikhailidis DP, Liberopoulos EN, et al. Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Nephrol Dial Transplant. 2007; 22(1):118-127.
37.
Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol. 2004;57(7):728-734.
